Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 1,
  • 9, 10 and
  • 1
BMC Urology201818:84

https://doi.org/10.1186/s12894-018-0397-5

  • Received: 21 September 2018
  • Accepted: 21 September 2018
  • Published:

The original article was published in BMC Urology 2018 18:77

Correction to Schultz et al. BMC Urology (2018) 18:77 DOI: 10.1186/s12894-018-0387-7

It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.

Incorrect:

The NNT for rPFS at 2 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

Correct:

The NNT for rPFS at 1 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, USA
(2)
Carolina Urologic Research Center, Myrtle Beach, SC, USA
(3)
Guy’s, King’s, and St. Thomas’ Hospitals, London, UK
(4)
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
(5)
Urology Associates, P.C, Nashville, TN, USA
(6)
Vanderbilt University Medical Center, Nashville, TN, USA
(7)
The Urology Center of Colorado, Denver, CO, USA
(8)
Analysis Group, Inc., Boston, MA, USA
(9)
Medivation, Inc., San Francisco, CA, USA
(10)
Pfizer, Inc., New York, NY, USA

Reference

  1. Schultz NM, et al. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018;18:77.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement